NAT-IMATINIB 100 MG
IMATINIB (IMATINIB MESYLATE) : 100 MG · DIN 02397285 · NATCO PHARMA (CANADA) INC
Health Canada status: MARKETED
What is NAT-IMATINIB?
NAT-IMATINIB 100 MG contains IMATINIB (IMATINIB MESYLATE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02397285, held by NATCO PHARMA (CANADA) INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NAT-IMATINIB used for?
Ph+ CML (newly diagnosed, blast crisis, accelerated phase, or post-interferon failure); Ph+ ALL; MDS/MPD; ASM; SM-AHNMD; HES/CEL; DFSP; Kit (CD117) positive GIST (unresectable/metastatic or adjuvant).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02397285 |
|---|---|
| Brand name | NAT-IMATINIB |
| Generic / active ingredient | IMATINIB (IMATINIB MESYLATE) : 100 MG |
| Manufacturer | NATCO PHARMA (CANADA) INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EA01 IMATINIB |
| AHFS class | 08:18.08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Aug-2017 |
How is it administered?
Adults: 400-600 mg/day (up to 800 mg/day as 400 mg BID). Pediatrics: 340 mg/m2/day. Administer orally with a meal and large glass of water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (refer to section 11).
How is it supplied?
100 mg: Cartons of 30 (3x10) or 120 (12x10) tablets. 400 mg: Cartons of 30 (3x10) tablets. Blister strips.
Contraindications
Hypersensitivity to imatinib or to any other component of NAT-IMATINIB.
Warnings and precautions
Severe CHF, LVEF reduction, rhabdomyolysis, severe hemorrhage, fluid retention, liver failure, gastrointestinal perforation, and Tumour Lysis Syndrome.
Is IMATINIB in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 22 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01EA01 IMATINIB. 16 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-IMATINIB | 100 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02490986 |
| ACH-IMATINIB | 400 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02490994 |
| APO-IMATINIB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02355337 |
| APO-IMATINIB | 400 MG | TABLET | APOTEX INC | MARKETED | DIN 02355345 |
| GLEEVEC | 100 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02253275 |
| GLEEVEC | 400 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02253283 |
| IMATINIB | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02504596 |
| IMATINIB | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02521202 |
| IMATINIB | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02504618 |
| IMATINIB | 400 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02521210 |
Who else supplies IMATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IMATINIB appears in 1741 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.